
Please try another search
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Mituaki Kamata | - | 2025 | EVP & Director |
Toshio Miyata | 64 | 2018 | CEO & Chairman |
Satoshi Kitaura | - | 2025 | Independent Outside Director |
Kazue Tsuji-Takayama | 59 | 2024 | Independent Outside Director |
Hideyuki Ito | 81 | 2022 | Alternate Outside Director |
Hiroaki Nogi | 66 | 2024 | Independent Outside Director |
Akihiko Ito | - | 2025 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review